FDA Flags Antibody Risk After Child's Death Linked To Takeda's Enzyme Replacement Therapy For Rare Blood Disorder

Why did Eli Lilly hit $1 trillion market cap? How is Nvidia's AI chip sale to China evolving? What impact will Tyson Foods' plant closure have? Why is Ukraine resisting the US peace plan? How did Trump’s tariff rollbacks affect Brazil imports? What caused the surge in disruptive airline passenger incidents? Why are tech stocks tumbling after Nvidia’s strong earnings?

FDA Flags Antibody Risk After Child's Death Linked To Takeda's Enzyme Replacement Therapy For Rare Blood Disorder

benzinga.com/news/fda/25/11/49012169/fda-flags-antibody-risk-after-childs-death-linked-to-takedas-enzyme-replacement-therapy-for-rare-blood-d

The U.S. Food and Drug Administration (FDA) on Friday said it has received postmarketing reports of neutralizing antibodies to ADAMTS13 in patients treated with Adzynma (recombinant ADAMTS13), including one pediatric death.
Takeda Pharmaceutical Co., Ltd. (NYSE:TAK) Adzynma is approved…

This story appeared on benzinga.com, 2025-11-21 18:43:16.